Categories AlphaGraphs, Earnings, Retail

Papa John’s report disappointing top and bottom line results for Q1

American restaurant franchise company Papa John’s International (PZZA), whose stock plunged 28% over the course of last one year and over 7% during last month, reported disappointing top and bottom line results for the first quarter 2018. Revenue dipped 4.9% to $427.3 million, while profit tanked 41.1% to $16.7 million or $0.50 per share. The revenue decline was mainly attributable to lower comparable sales for the company’s North America restaurants and declining North America commissary sales attributable to lower volumes.

The pizza company has had a bad patch since the termination of the company’s partnership with NFL and has had reported negative comparable store sales in North America for the first time in over a couple of years.  However, International comparable store sales saw some marginal increase.

Papa John's earnings

For the quarter, Papa John’s North America comparable sales declined 5.3%, while international comparable sales inched up 0.3%.  The international comp sale increase was aided by international franchise sales increase of 21.1%. The pizza chain also opened 13 new units in the first quarter, driven by its international operations. Favorable foreign exchange rates helped the company report positive results for its international operations.

“Although first quarter results were lower than the prior year, they were consistent with our expectations. We remain focused on enhancing our value perception and driving our strategic initiatives,” said Steve Ritchie, CEO.

Papa John’s reaffirmed its previous fiscal year 2018 outlook of diluted earnings per share in the range of $2.40 to $2.60. The company also reaffirmed its previous comparable sales outlook for North America in the range of negative 3% to flat, with international comparable sales expected between 3% and 5%.

The company’s stock plunged almost 5% post the earnings release on the disappointing results.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top